Pursuant to the terms of the agreement, Terumo Cardiovascular will begin distributing Nonin Medical’s product with effect from January 2014.

SenSmart universal oximetry system provides measurements of regional oximetry (rSO2) and pulse oximetry (SpO2). It provides comprehensive monitoring of up to six-channels of rSO2 and SpO2 monitoring.

SenSmart system features a signal processor that is substantially smaller than previous versions. This makes the SenSmart system ideal for use in a variety of settings where space is an issue, such as neonatal incubators.

The system allows anesthesiologists, perfusionists, cardiovascular surgeons, neonatologists, intensivists, and other clinicians to quickly react to reverse tissue ischemia events before they become critical.

Nonin Medical business development vice president Chris Holland noted the company is pleased that this agreement, which takes advantage of Terumo’s extensive cardiovascular relationships in heart hospitals in the UK and Ireland, will accelerate the adoption of the SenSmart system in the UK and Ireland.

"Nonin’s SpO2 and rSO2 technologies are cost-effective monitoring tools that help aid clinicians in caring for their patients with early detection of potentially dangerous events," Holland added.

In April 2013, Nonin Medical and Terumo Cardiovascular have signed a distribution agreement for the SenSmart universal oximetry system in the US.